查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
血铁沉着症治疗的全球市场 - 2022年～2029年
市场调查报告书
商品编码
1077273

血铁沉着症治疗的全球市场 - 2022年～2029年

Global Hemochromatosis Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告提供全球血铁沉着症治疗市场相关调查，提供市场概要，各类型，各诊断类型，不同治疗，各终端用户，各流通管道，各地区趋势，竞争情形，及加入此市场的主要企业简介等资讯。

目录

第1章 调查手法和范围

第2章 市场定义和概要

第3章 摘要整理

  • 各类型，市场明细
  • 各诊断类型，市场明细
  • 不同治疗，市场明细
  • 各终端用户，市场明细
  • 各流通管道，市场明细
  • 各地区，市场明细

第4章 市场动态

  • 影响市场的要素
    • 促进因素
    • 阻碍因素
    • 市场机会
    • 影响分析

第5章 产业分析

  • 供应链分析
  • 价格分析
  • 未满足需求

第6章 COVID-19分析

第7章 各类型

  • 简介
    • 市场规模分析，及与前一年同期比较成长分析(%)、各类型
    • 市场魅力指数，各类型
  • 原发性血铁沉着症
    • 青年性血铁沉着症
    • 新生儿血铁沉着症
    • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
  • 次发性血铁沉着症

第8章 各诊断类型

  • 简介
    • 市场规模分析，及与前一年同期比较成长分析(%)、各诊断类型
    • 市场魅力指数，各诊断类型
  • 血液检验
    • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
  • CT(电脑断层设备)
  • MRI(核磁共振影像)
  • 肝臟切片检查
  • 其他

第9章 不同治疗

  • 简介
    • 市场规模分析，及与前一年同期比较成长分析(%)、不同治疗
    • 市场魅力指数，不同治疗
  • 放血疗法
    • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
  • 螫合物疗法
    • Deferasirox
    • Deferoxamine
    • Deferiprone
    • 其他
  • 手术
  • 其他

第10章 各终端用户

  • 简介
    • 市场规模分析，及与前一年同期比较成长分析(%)、各终端用户
    • 市场魅力指数，各终端用户
  • 医院
    • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
  • 诊断中心
  • 外科门诊诊疗所
  • 其他

第11章 各流通管道

  • 简介
    • 市场规模分析，及与前一年同期比较成长分析(%)、各流通管道
    • 市场魅力指数，各流通管道
  • 院内药局
    • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
  • 零售药局
  • 线上药局
  • 其他

第12章 各地区

  • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)，各地区
    • 市场魅力指数，各地区
  • 北美
  • 欧洲
  • 南美
  • 亚太地区
  • 中东·非洲

第13章 竞争情形

  • 主要的发展与策略
  • 企业占有率分析
  • 产品的基准
  • 值得注意的主要企业的清单

第14章 企业简介

  • Novartis Pharmaceuticals Corporation
  • Camber Pharmaceuticals, Inc.
  • Novadoz Pharmaceuticals
  • Teva Pharmaceuticals USA, Inc.
  • Pfizer Inc.
  • Merck KGaA
  • Abcam plc.
  • ApoPharma Inc.
  • CHIESI FARMACEUTICI S.p.A
  • Apotex Inc.

第15章 全球血铁沉着症治疗市场-DataM

简介目录
Product Code: DMPH5055

Market Overview

The global hemochromatosis treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Hemochromatosis, also known as bronze diabetes or iron storage disease, is an autosomal recessive hereditary disorder characterized by excessive iron absorption by the small intestines. Excess iron accumulation in the body promotes oxidation and causes tissue injury, fatigue, arthralgia or arthritis, and skin changes. Hemochromatosis is treated with phlebotomy, and Chelation therapy is the most direct and safe way to lower body stores of iron.

Market Dynamics

Technological advancement in the detection of liver disease is expected to drive market growth.

Glycocholic acid (GCA) is a biomarker for liver disorders, but until now, only a few simple naked-eye detection methods have been published. A hybridoma approach is used to create a new monoclonal mouse antibody (mAb) against GCA. The anti-GCA mAb had a good specificity, resulting in little cross-reactivity with seven structurally and functionally related GCA analogs. A simple naked-eye visible approach for GCA detection was devised using this anti-GCA mAb and a modified red-colored bacterial strain (Staphylococcus aureus, S. aureus). This approach of detecting GCA with just your eyes takes only a few minutes and does not require any expensive equipment. It is a quick, convenient, and straightforward approach for detecting GCA to diagnose liver disorders. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Stringent regulatory processes, lack of awareness of the disease, and scarcity of accessibility of drugs are some of the factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Iron deficiency is becoming more widely recognized as a factor in COVID-19 etiology. COVID-19's symptoms, including inflammation, hypercoagulation, hyperferritinemia, and immunological dysfunction, are similar to iron overload. The major pathogenic molecular step of COVID-19, according to researchers, is to target hemoglobin, causing the porphyrins to dissociate from iron and release iron into circulation. As a result, hemoglobin loses its ability to bond with oxygen, obstructing oxygen supply to important organs and resulting in fast multi-organ failure. Iron chelation can be used as adjuvant therapy to treat COVID-19. In addition to the naturally occurring iron chelator lactoferrin, iron chelators such as deferasirox, deferoxamine, and deferiprone may be beneficial in the fight against COVID-19. Iron chelators may be useful not just for sequestering iron and reducing inflammation but also for blocking the coronavirus from attaching to the receptors it uses to enter host cells.

Additionally, the pandemic is interrupting the supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the COVID-19 pandemic has affected the market.

Segment Analysis

Phlebotomy segment is expected to hold the largest market share in hemochromatosis treatment market

The phlebotomy segment is expected to dominate in 2020. The segment is benefited because phlebotomy, or the removal of excess iron from the blood, is used to treat hemochromatosis. This method has maintained the iron levels in the blood in check by drawing blood from the patient regularly. Giving blood is a similar procedure. Phlebotomy is a simple, inexpensive, and risk-free career. Phlebotomy is mostly done in blood banks, like conventional blood donation. Phlebotomy can help people who haven't yet experienced problems due to an excess of iron. It could also help you live a normal life expectancy. For instance, phlebotomy can help avoid cirrhosis and its potentially lethal effects, such as liver cancer. Poor liver function, liver enlargement, and liver pain are all conditions that can be treated or improved. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

Europe region holds the largest market share in the global hemochromatosis treatment market

In 2020, Europe accounted for the highest revenue share. The increasing prevalence of hemochromatosis, advancement in diagnosis procedures, and growing investment in research and development activities of hemochromatosis in the region are factors the market is expected to boost in the forecast period. For instance, The European countries with the highest prevalence include Ireland, France, and Denmark. Hemochromatosis is one of the most common heritable genetic conditions in people of Northern Europe, with a prevalence of 1:200. The disease has a variable penetration and about one in 10 people of this demographic carry a mutation in one of the genes regulating iron metabolism.

Moreover, Silence Therapeutics' primary RNAi drug in development intends to cure and reverse iron diseases, such as beta-thalassemia, myelodysplastic syndrome, and hemochromatosis, famously underdiagnosed and undertreated. Targeting a protein called hepcidin, a critical iron balance regulator in the body, the company's technique could lower iron levels in the blood. Therefore, it has increased the demand for hemochromatosis treatment, due to which the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the hemochromatosis treatment market are Novartis Pharmaceuticals Corporation, Camber Pharmaceuticals, Inc., Novadoz Pharmaceuticals, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Merck KGaA, Abcam plc., ApoPharma Inc., CHIESI FARMACEUTICI S.p.A and Apotex Inc.

Pfizer, Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company. The company develops and produces medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. Its medicines and vaccines provide value for healthcare providers and patients through the treatment of diseases improvements in health wellness. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.

­Product Portfolio:

DEFEROXAMINE MESYLATE (deferoxamine mesylate): Deferoxamine Mesylate for Injection, USP is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias.

Why Purchase the Report?

Visualize the composition of the hemochromatosis treatment market segmentation by type, diagnosis type, treatment, end user, distribution channel and region highlighting the key commercial assets and players.

Identify commercial opportunities in hemochromatosis treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of hemochromatosis treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global hemochromatosis treatment market report would provide an access to an approx. 45+market data table, 40+figures and 200pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Diagnosis Type
  • 3.3. Market Snippet by Treatment
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Distribution Channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancement in the detection of liver disease is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Stringent regulatory processes and lack of awareness of the disease is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Primary Hemochromatosis*
    • 7.2.1. Juvenile Hemochromatosis
    • 7.2.2. Neonatal Hemochromatosis
    • 7.2.3. Introduction
    • 7.2.4. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Secondary Hemochromatosis

8. By Diagnosis Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    • 8.1.2. Market Attractiveness Index, By Diagnosis Type Segment
  • 8.2. Blood test*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. CT (computerized topography)
  • 8.4. MRI (magnetic resonance imaging)
  • 8.5. Liver biopsy
  • 8.6. Others

9. By Treatment

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.1.2. Market Attractiveness Index, By Treatment Segment
  • 9.2. Phlebotomy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Chelation Therapy
    • 9.3.1. Deferasirox
    • 9.3.2. Deferoxamine
    • 9.3.3. Deferiprone
    • 9.3.4. Others
  • 9.4. Surgery
  • 9.5. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Center
  • 10.4. Ambulatory Surgical Center
  • 10.5. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Type
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Type
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Type
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Type
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Type
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch

14. Company Profiles

  • 14.1. Novartis Pharmaceuticals Corporation*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Camber Pharmaceuticals, Inc.
  • 14.3. Novadoz Pharmaceuticals
  • 14.4. Teva Pharmaceuticals USA, Inc.
  • 14.5. Pfizer Inc.
  • 14.6. Merck KGaA
  • 14.7. Abcam plc.
  • 14.8. ApoPharma Inc.
  • 14.9. CHIESI FARMACEUTICI S.p.A
  • 14.10. Apotex Inc.

LIST NOT EXHAUSTIVE

15. Global Hemochromatosis Treatment Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Applications
  • 15.3. Contact Us